These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35578820)

  • 21. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
    Jabbari A; Nguyen N; Cerise JE; Ulerio G; de Jong A; Clynes R; Christiano AM; Mackay-Wiggan J
    Exp Dermatol; 2016 Aug; 25(8):642-3. PubMed ID: 27119625
    [No Abstract]   [Full Text] [Related]  

  • 22. Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: A prospective, open-label, single-center study in Asian Arab population.
    Husein-ElAhmed H; Abdulla N; Al-Obaidli A; Ali-Alam M; Steinhoff M
    Dermatol Ther; 2022 Dec; 35(12):e15871. PubMed ID: 36177791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population.
    AlMarzoug A; AlOrainy M; AlTawil L; AlHayaza G; AlAnazi R; AlIssa A; AlSheikh A; AlKhalifah A; AlHarithy R
    Int J Dermatol; 2022 Jul; 61(7):886-894. PubMed ID: 34716573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic synergy between contact dermatitis from a wig-fixing device and tofacitinib on alopecia areata.
    Lee JS; Yoon HS; Cho S; Park HS
    J Dermatol; 2019 Apr; 46(4):e139-e140. PubMed ID: 30204259
    [No Abstract]   [Full Text] [Related]  

  • 25. Oral tofacitinib for successful treatment of refractory alopecia areata in preschool children.
    Geng SL; Gong T; Ji C; Su HH
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):e1055-e1057. PubMed ID: 35876014
    [No Abstract]   [Full Text] [Related]  

  • 26. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata.
    Wambier CG; Craiglow BG; King BA
    J Am Acad Dermatol; 2021 Sep; 85(3):743-745. PubMed ID: 31499158
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis.
    Dincer D; Tanacan E; Kose Ozkan C
    J Cosmet Dermatol; 2021 Jun; 20(6):1807-1809. PubMed ID: 33098729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata.
    Liu LY; King BA
    J Am Acad Dermatol; 2019 Jun; 80(6):1778-1779. PubMed ID: 30502414
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of Alopecia Areata With Tofacitinib.
    Ibrahim O; Bayart CB; Hogan S; Piliang M; Bergfeld WF
    JAMA Dermatol; 2017 Jun; 153(6):600-602. PubMed ID: 28355451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tofacitinib as a treatment of alopecia areata in adolescents.
    Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R
    Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral tofacitinib for the treatment of alopecia areata in pediatric patients.
    Kibbie J; Kines K; Norris D; Dunnick CA
    Pediatr Dermatol; 2022 Jan; 39(1):31-34. PubMed ID: 34779041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ruxolitinib for the treatment of severe alopecia areata.
    Liu LY; King BA
    J Am Acad Dermatol; 2019 Feb; 80(2):566-568. PubMed ID: 30195572
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
    Yu DA; Kim YE; Kwon O; Park H
    Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
    Liu LY; King BA
    J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S18-S20. PubMed ID: 29273099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic.
    Aşkın Ö; Özkoca D; Uzunçakmak TK; Serdaroğlu S
    Dermatol Ther; 2021 Mar; 34(2):e14746. PubMed ID: 33405372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
    Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
    JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
    Brown L; Skopit S
    J Drugs Dermatol; 2018 Aug; 17(8):914-917. PubMed ID: 30124734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
    Salman A; Sarac G; Ergun T
    Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New developing multiple sclerosis in a patient using tofacitinib due to alopesia areata.
    Erçoban R; İslamoğlu ZGK
    Dermatol Ther; 2022 Jun; 35(6):e15477. PubMed ID: 35355384
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.